• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    6/13/25 6:19:04 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care
    Get the next $INSP alert in real time by email
    insp-20250613
    0001609550False00016095502025-06-132025-06-13


    SECURITIES AND EXCHANGE
    Washington, D.C. 20549
    _________________________
    FORM 8-K
    _________________________
    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): June 13, 2025
    _________________________
    INSPIRE MEDICAL SYSTEMS, INC.
    (Exact name of registrant as specified in its charter)
    _________________________
    Delaware001-3846826-1377674
    (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
    5500 Wayzata Blvd., Suite 1600
    Golden Valley, Minnesota 55416
    (Address of principal executive offices) (Zip Code)

    (844) 672-4357
    (Registrant’s telephone number, including area code)

    N/A
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par value per shareINSPNew York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company     ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
    period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 7.01. Regulation FD Disclosure.
    In June 2025, the Company will be participating in various meetings with investors and analysts, and a copy of the Company’s presentation materials being used at these meetings is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. These presentation materials are also available on the Investor Relations page of the Company’s website at https://investors.inspiresleep.com.

    The information in Item 7.01 of this Current Report on Form 8-K and the presentation attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits

    Exhibit No.Description
    99.1
    Inspire Medical Systems, Inc. Presentation dated June 13, 2025.
    104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    INSPIRE MEDICAL SYSTEMS, INC.
    Date:June 13, 2025By:/s/ Richard J. Buchholz
    Richard J. Buchholz
    Chief Financial Officer

    3
    Get the next $INSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INSP

    DatePrice TargetRatingAnalyst
    11/20/2024$220.00 → $255.00Neutral → Buy
    BofA Securities
    5/8/2024$265.00 → $225.00Buy → Neutral
    BofA Securities
    4/19/2024$285.00Outperform
    RBC Capital Mkts
    3/19/2024$250.00Overweight
    Morgan Stanley
    2/6/2024$278.00Overweight
    KeyBanc Capital Markets
    1/19/2024$245.00Buy
    Jefferies
    1/2/2024$210.00Buy → Hold
    Stifel
    12/13/2023$245.00 → $187.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $INSP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inspire Medical Systems, Inc. to Present at the Truist Securities MedTech Conference

      MINNEAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025. Inspire is scheduled to present at 11:20 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investors.inspiresl

      6/3/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

      MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investor

      5/30/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook

      Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 million in the first quarter of 2025, a 23% increase over the same quarter last yearAchieved gross margin of 84.7% in the first quarter of 2025Generated earnings per share of $0.10 in

      5/5/25 4:02:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Inspire Medical Systems upgraded by BofA Securities with a new price target

      BofA Securities upgraded Inspire Medical Systems from Neutral to Buy and set a new price target of $255.00 from $220.00 previously

      11/20/24 7:43:58 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems downgraded by BofA Securities with a new price target

      BofA Securities downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $225.00 from $265.00 previously

      5/8/24 7:48:44 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • RBC Capital Mkts initiated coverage on Inspire Medical Systems with a new price target

      RBC Capital Mkts initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $285.00

      4/19/24 7:26:47 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mccormick Shawn exercised 4,000 shares at a strike of $16.00, increasing direct ownership by 17% to 28,046 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      6/6/25 6:06:02 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Officer Rondoni John sold $259,025 worth of shares (1,734 units at $149.38), decreasing direct ownership by 11% to 13,766 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      5/21/25 4:05:14 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Director Ellis Gary Lee was granted 1,266 shares, increasing direct ownership by 28% to 5,861 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      5/5/25 8:26:47 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Financials

    Live finance-specific insights

    See more
    • Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook

      Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 million in the first quarter of 2025, a 23% increase over the same quarter last yearAchieved gross margin of 84.7% in the first quarter of 2025Generated earnings per share of $0.10 in

      5/5/25 4:02:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025

      MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q1 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following l

      4/1/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results and Updates 2025 Outlook

      MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024. Recent Business Highlights and Full Year 2025 Guidance Generated revenue of $239.7 million for the fourth quarter of 2024, a 25% increase over the same quarter last year, and revenue of $802.8 million for full year 2024, a 28% increase over full year 2023Achieved gross margin of 85.0% for the fourth quarter of 2024Repo

      2/10/25 4:02:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    SEC Filings

    See more
    • Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)

      6/13/25 6:19:04 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Inspire Medical Systems Inc.

      SD - Inspire Medical Systems, Inc. (0001609550) (Filer)

      5/30/25 4:12:28 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Inspire Medical Systems Inc.

      144 - Inspire Medical Systems, Inc. (0001609550) (Subject)

      5/19/25 4:01:53 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sparks Charisse Y bought $15,350 worth of shares (100 units at $153.50), increasing direct ownership by 11% to 998 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      1/24/24 4:32:03 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Leadership Updates

    Live Leadership Updates

    See more
    • Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

      MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

      4/21/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Presidio Medical™ Announces Appointment of Richard J. Buchholz to Join its Board of Directors

      Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. "We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company's journey. His leadership and financial acumen will be instrumental in advanc

      12/5/24 12:12:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      11/12/24 10:32:14 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      10/4/24 2:09:06 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inspire Medical Systems Inc. (Amendment)

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      2/13/24 5:06:20 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 21, 2023 - FDA Roundup: March 21, 2023

      For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

      3/21/23 3:12:46 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care